Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen Talks Dual Pricing Strategy For Amjevita

Debut US Humira Biosimilar Has Been Priced To Address ‘Complexity Of The US Market’

Executive Summary

In the wake of Amgen announcing a dual pricing strategy for its debut US adalimumab biosimilar – with the firm’s newly-launched Amjevita version being offered at both 5% off and 55% off the WAC of the Humira original – investors and analysts were keen to press the firm for further details of its pricing strategy.

You may also be interested in...

US Amjevita Sales Slide By Almost Two-Thirds

Amgen has revealed a significant – albeit expected – drop in second-quarter sales figures for its Amjevita US biosimilar rival to Humira.

Savvy Pricing Practices Enabling Deep Discounts For Adalimumab And Glargine

The second quarterly report on the biosimilars industry from Samsung Bioepis has drawn attention to how pricing strategies are being used to enable discounts for adalimumab and insulin glargine.

US Biosimilars Need Access In Exchange For Industry Commitment

As the dust settles after a wave of fresh adalimumab biosimilar launches, the US Biosimilars Forum’s executive director Julie Reed talks to Generics Bulletin about how other stakeholders need to step up to meet industry’s commitment to the sector – as well as how PBMs are distorting the market and streamlined regulation is needed to drive competition.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts